Anti-TFPI Antibody (Concizumab)
Catalog No.
F1698
Anti-TFPI Antibody (Concizumab)
Featured Products
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 domain of TFPI, thereby blocking the interaction of this domain with the FXa active site. Concizumab can be used in the study of hemophilia.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
1312299-39-0
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
NNC-0172-0000-2021, NN-7415
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P10646
Human, Cynomolgus, Rhesus, Rabbit
Unconjugated
Monoclonal
Protein A
IgG4SP
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human TFPI, Fc Tag at 2 ug/mL can bind Anti-TFPI Antibody (Concizumab)
TFPI
Please avoid freeze-thaw cycles.